Spinal Musküler Atrofiye Güncel Bakış

Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. The application of clinical genetics. 2021;14:11–25.

Hahnen E, Forkert R, Marke C, et al. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Human molecular genetics.1995;4:1927-1933. doi:10.1093/hmg/4.10.1927

Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscular disorders. 2018;28(3):208-215. doi:10.1016/j.nmd.2018.01.003

Arikan Y, Berker Karauzum S, Uysal H, et al. Evaluation of exonic copy numbers of SMN1 and SMN2 genes in SMA. Gene. 2022;823:146322. doi:10.1016/j.gene.2022.146322

Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet journal of rare diseases. 2017;12(1):124. doi:10.1186/s13023-017-0671-8

Li C, Geng Y, Zhu X, et al. The prevalence of spinal muscular atrophy carrier in China: Evidences from epidemiological surveys. Medicine. 2020;99(5):e18975. doi:10.1097/MD.0000000000018975

Coratti G, Ricci M, Capasso A, et al. Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey [published online ahead of print, 2022 Dec 2]. Neurology. 2022;10.1212/WNL.0000000000201654. doi:10.1212/WNL.0000000000201654

Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. Journal of child neurology. 2007;22(8):946-951. doi:10.1177/0883073807305673

Munsat TL, Davies KE. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscular disorders. 1992;2(5-6):423-428. doi:10.1016/s0960-8966(06)80015-5

Arnold WD, Flanigan KM. A practical approach to molecular diagnostic testing in neuromuscular diseases. Physical medicine and rehabilitation clinics of North America. 2012;23(3):589-608. doi:10.1016/j.pmr.2012.06.002

Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Human genetics. 2002;111(6):477-500. doi:10.1007/s00439-002-0828-x

Stevens D, Claborn MK, Gildon BL, et al. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. The Annals of pharmacotherapy. 2020;54(10):1001-1009. doi:10.1177/1060028020914274

Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology. 2021;20(4):284-293. doi:10.1016/S1474-4422(21)00001-6

Day JW, Mendell JR, Mercuri E, et al. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug safety. 2021;44(10):1109-1119. doi:10.1007/s40264-021-01107-6

Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64(4):413-427. doi:10.1002/mus.27363

Ratni H, Scalco RS, Stephan AH. Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines. ACS medicinal chemistry letters. 2021;12(6):874-877. doi:10.1021/acsmedchemlett.0c00659

Dhillon S. Risdiplam: First Approval. Drugs. 2020;80(17):1853-1858. doi:10.1007/s40265-020-01410-z